GlassScriptPhysician profile
Nicholas A Cook
NPI 1114015989
$1,266.89
in general payments reported to CMS, 2019-2025
22 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2021: $139 · 2022: $206 · 2023: $257 · 2024: $51.25 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $401 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $401.34 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $232.02 | 2019-2024 | Evenity, Prolia, Xgeva |
| Pharmacyclics LLC, An Abbvie Company | $146.54 | 2019-2023 | Imbruvica |
| Seagen INC. | $132.19 | 2022-2023 | Tukysa |
| Janssen Biotech, INC. | $114.42 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| E.R. Squibb & Sons, L.L.C. | $109.44 | 2019 | |
| Celgene Corporation | $97.77 | 2019-2025 | Reblozyl, Pomalyst |
| Daiichi Sankyo INC. | $82.80 | 2022-2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $42.30 | 2025 | |
| Genzyme Corporation | $41.58 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $36.03 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.30 | 2019-2022 | |
| Secura Bio, INC. | $29.01 | 2019 | |
| Tesaro, INC. | $24.68 | 2019 | |
| Eisai INC. | $22.88 | 2019 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $19.07 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $17.27 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.69 | 2019 | |
| Glaxosmithkline, LLC. | $13.05 | 2021 | |
| Alexion Pharmaceuticals, INC. | $12.50 | 2019 | |
| Incyte Corporation | $12.43 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.